<div>In today’s episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a professor of medicine at Heidelberg University in Germany.</div>

In today’s episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a professor of medicine at Heidelberg University in Germany.

S14 Ep53: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S14 Ep53: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

Sign up to save your podcasts

S14 Ep53: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

S14 Ep53: Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

More shows like OncLive® On Air

JAMA Clinical Reviews

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

ASCO Daily News

The Daily

OncoPharm

The Readout Loud

The Uromigos

Oncology Today with Dr Neil Love

BioCentury This Week

CCO Oncology Podcast

Biotech Hangout

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions